08
Apr
JENKINTOWN, PA, UNITED STATES, April 8, 2021 /EINPresswire.com/ — SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start of our first clinical trial for the treatment of “the appearance of the structure of skin with plaques due to psoriasis.” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial.
This 30-subject open-label clinical trial in...
Read More